GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. Hoos is leaving GSK after nine ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

These caterpillars carry a toxic chemical cocktail and Inquisition-like delivery implements—and their geographic range is ...

But, as this special report snapshot shows, a host of new trials and targeted therapeutics are beginning to show serious dividends.

ASX rises despite Wall Street dip, Alibaba’s AI shakes Nvidia, Lovisa hit with class action and IGO posts quarterly earnings ...

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: January 29 at 4:08:12 PM EST Loading Chart for IPSC ...

Dyne Therapeutics Inc. 4.43% $1.38B ...